| Name | Title | Contact Details |
|---|---|---|
Ivor D`Souza |
Acting Director of Center for Information Technology | Profile |
Andrea Ramirez |
Chief Data Officer | Profile |
Connie Latzko |
Chief Information Officer, National Institute on Deafness and Other Communication Disorders (NIDCD) | Profile |
David Olson |
Chief Information Security Officer | Profile |
Ramesh Varanasi |
Deputy Chief Information Security Officer | Profile |
Coshocton County Memorial Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Coshocton County Memorial Hospital is based in Coshocton, OH. You can find more information on Coshocton County Memorial Hospital at www.ccmh.com
MC-21 is a Caguas, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Georgia Cancer Specialists is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Georgia Cancer Specialists is based in Atlanta, GA. You can find more information on Georgia Cancer Specialists at www.gacancer.com
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
What if one solution could change everything you thought you knew about Diabetes?